

**Filed On Behalf Of:**  
Novartis Pharmaceuticals Corporation

**By:**  
Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED.**

Petitioner,

v.

**NOVARTIS PHARMACEUTICALS CORPORATION,**

Patent Owner.

---

Case IPR2017-01592<sup>1</sup>

Patent No. 8,410,131

---

**PATENT OWNER'S EXHIBIT LIST 10**

---

<sup>1</sup> IPR2018-00507 has been joined to this proceeding (Paper 29, Apr. 03, 2018).

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2001</b>	Expert Declaration Of Howard A. Burris, III, M.D.	<b>Burris Decl.</b>
<b>2002</b>	Curriculum Vitae Of Howard A. Burris, III, M.D.	<b>Burris C.V.</b>
<b>2003</b>	Laughlin, E.H., <i>Coming To Terms With Cancer: A Glossary Of Cancer-Related Terms</i> , pages 4, 126, 140, 173-174, 188-190 (2002)	<b>Laughlin</b>
<b>2004</b>	Altman, R. & Sarg, M.J., <i>The Cancer Dictionary</i> , 51-52, 278 (1992)	<b>Altman</b>
<b>2005</b>	Sutcliffe, S.B. & Gospodarowicz, M.K., Chapter 25, "Primary Extranodal Lymphomas," <i>The Lymphomas</i> (Canellos, G.P. et al. eds., 1998)	<b>Sutcliffe 1998</b>
<b>2006</b>	Molina, A. & Pezner, R.D., Chapter 30, "Non-Hodgkin's Lymphoma," <i>Cancer Management: A Multidisciplinary Approach: Medical, Surgical, &amp; Radiation Oncology</i> , 4th Edition (Pazdur, R. et al. eds., 2000)	<b>Pazdur</b>
<b>2007</b>	Sutcliffe, S.B. & Gospodarowicz, M.K., "Clinical Features And Management Of Localized Extranodal Lymphomas," <i>Haematological Oncology</i> , Volume 2 pages 189-222 (Keating, A. et al. eds., 1992)	<b>Sutcliffe</b>
<b>2008</b>	Lynch, C.F. & Cohen, M.B., "Urinary System," <i>Cancer</i> 75(1 Suppl.): 316-329 (1995)	<b>Lynch</b>
<b>2009</b>	Ligato, S. et al., "Benign Tumors And Tumor-Like Lesions Of The Adult Kidney Part I: Benign Renal Epithelial Neoplasms," <i>Adv. Anat. Pathol.</i> 6(1): 1-11 (1999)	<b>Ligato</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2010</b>	Glenn, G.M. et al., Chapter 75, "The Molecular Genetics Of Renal Cell Carcinoma," <i>Principles And Practice Of Genitourinary Oncology</i> (Raghavan, D. et al. eds., 1997)	<b>Glenn</b>
<b>2011</b>	Hyland, S. & Wilkinson, D., Chapter 14, "The Nurse Practitioner And The Organization Of Support Services For The Patient With Genitourinary Cancer," <i>Principles And Practice Of Genitourinary Oncology</i> (Raghavan, D. et al. eds., 1997)	<b>Hyland</b>
<b>2012</b>	Vasey, P.A., "Immunotherapy For Renal Carcinoma: Theoretical Basis And Current Standard Of Care," <i>Br. J. Clin. Pharmacol.</i> 50: 521-529 (2000)	<b>Vasey</b>
<b>2013</b>	Kawai, K. et al., "Ex Vivo Gene Therapy Using Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Tumor Vaccines," <i>Mol. Urol.</i> 4(2): 43-46 (2000)	<b>Kawai</b>
<b>2014</b>	Adjei, A.A., "Signal Transduction Pathway Targets For Anticancer Drug Discovery," <i>Cur. Pharm. Design</i> 6: 361-378 (2000)	<b>Adjei</b>
<b>2015</b>	Gordon, M.S. et al., "Phase I Safety And Pharmacokinetic Study Of Recombinant Human Anti-Vascular Endothelial Growth Factor In Patients With Advanced Cancer," <i>J. Clin. Oncol.</i> 19(3): 843-850 (2001)	<b>Gordon</b>
<b>2016</b>	Penn, I. & Starzl, T.E., "Immunosuppression And Cancer," <i>Transplant Proc.</i> 5(1): 943-947 (1973)	<b>Penn</b>
<b>2017</b>	January 19, 2016 Office Action, Prosecution File History Of U.S. Patent Application No. 13/893,537	

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2018</b>	January 27, 2016 Office Action, Prosecution File History Of U.S. Patent Application No. 13/893,589	
<b>2019</b>	October 17, 2006 Official Communication and February 26, 2007 Applicant Response (received February 27, 2007), Prosecution File History Of European Patent Application No. 01 903 095.6-2112 (International Application No. PCT/US01/01537)	
<b>2020</b>	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Christina Schwarz Under 37 C.F.R. § 42.10	
<b>2021</b>	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Charlotte Jacobsen Under 37 C.F.R. § 42.10	
<b>2022</b>	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Susanne L. Flanders Under 37 C.F.R. § 42.10	
<b>2023</b>	Kozlowski, J.M. et al., Chapter 78, "Renal Cell Carcinoma, Tumor Markers," <i>Principles And Practice Of Genitourinary Oncology</i> (Raghavan, D. et al. eds., 1997)	<b>Kozlowski</b>
<b>2024</b>	Motzer, R.J. & Russo, P., "Systemic Therapy For Renal Cell Carcinoma," <i>J. Urology</i> 163:408-417 (2000)	<b>Russo</b>
<b>2025</b>	Physicians' Desk Reference, 55th Edition (2001), pages 3443-3448 (Entry for Rapamune® Oral Solution (Sirolimus))	<b>Rapamune® PDR</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2026</b>	Document Stamped At The March 13, 2018 Deposition Of Dr. Allan J. Pantuck	
<b>2027</b>	March 13, 2018 Deposition Testimony of Dr. Allan J. Pantuck	<b>Pantuck</b>
<b>2028</b>	Truong, L. et al., "The Diagnostic and Therapeutic Roles of Fine-Needle Aspiration," <i>Am. J. Clin. Pathol.</i> 115:18-31 (2001)	<b>Truong</b>
<b>2029</b>	Hanahan, D. & R.A. Weinberg, "The Hallmarks of Cancer," <i>Cell</i> 100:57-70 (2000)	<b>Hanahan</b>
<b>2030</b>	Abbas, Z. et al., "Renal lymphoma: an unusual cause of extrahepatic biliary obstruction," <i>Postgraduate Med. J.</i> 617-18 (1996)	<b>Abbas</b>
<b>2031</b>	"Genitourinary," <i>Stedman's Medical Dictionary</i> 738-39 (27 <sup>th</sup> ed. 2000)	<b>Stedman's</b>
<b>2032</b>	Braybrooke, J.P. et al., "A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis," <i>Clin. Cancer Res.</i> 6:4697-4704 (2000)	<b>Braybrooke</b>
<b>2033</b>	"Proleukin <sup>®</sup> ," <i>Physicians' Desk Reference<sup>®</sup></i> , 874-78 (47 <sup>th</sup> ed. 1993)	<b>Proleukin<sup>®</sup> PDR</b>
<b>2034</b>	Yagoda, A. et al., "Chemotherapy for Advanced Renal-Cell Carcinoma: 1983-1993," <i>Seminars Oncol.</i> 22(1):42-60 (1995)	<b>Yagoda</b>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.